Scinai Immunotherapeutics

Scinai Immunotherapeutics

Biotechnology
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

$12.2M

Market Cap • 9/11/2026

2003

(23 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Israel

Israel

Country

Valuation

P/B

1

P/S

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

2,2

EPS

0,2

Market Cap

Market Cap

12,2M

EV

18,7M

EV/Revenue

0

EV/EBITDA

0

EV/EBIT

0

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-124,3M

Profitability

Gross Margin

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

% PPE

79,7%

% Goodwill

0%

ROE

ROIC

Growth

CAGR Op. Income 5Y

-100%

CAGR Net Income 5Y

-100%

CAGR OCF 5Y

-100%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

1,6

Quick Ratio

1,2

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium